STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-08-16
Here’s whether Amgen Inc (AMGN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.07% over 10 days); strong 1-year return of +43.0%; 3-month momentum positive (+27.2%). Concerns: RSI 73 — overbought, elevated pullback risk. Currently 1.6% off its 52-week high. Score: +5/7.
AMGN is in a confirmed uptrend, trading above both its 50-day ($370.22) and 200-day ($349.39) moving averages. With an RSI of 73.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +43.0% compares to +20.4% for SPY (beat the market by 22.7%).
$10,000 invested 1 year ago→ $14,303 today
vs. S&P 500 (SPY) — same period beat market by 22.7%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($349.39)
✓Above 50-day MA ($370.22)
!RSI(14) neutral zone (30–70) — currently 73.1
✓Positive return (+43.0%)
✓Within 10% of period high (−1.6%)
Period Range $415.21
$269.77$421.79
RSI (14) 73.1
0 · OversoldOverbought · 100
Key Metrics
Price$415.21
Period Return+43.0%
Period High$421.79
Period Low$269.77
Drawdown−1.6%
MA-50$370.22
MA-200$349.39
RSI (14)73.1
Avg Volume (30d)2.5M
vs. SPYbeat by 22.7%
Return Rank#339 of 1252
Trend Signals
Price is above the 200-day moving average ($349.39)
Price is above the 50-day moving average ($370.22)